Federal contractor · SAN FRANCISCO, CA

VIVID BIOINNOVATIONS, PBC

No contract obligations recorded for VIVID BIOINNOVATIONS, PBC in FY2026. Since FY2023: $895.2K. It also received $3.8M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
Q1NZN4P95F83
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 299.9KFY2023
  2. 595.3KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for VIVID BIOINNOVATIONS, PBC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

VIVID BIOINNOVATIONS, PBC received $3.8M in federal assistance in FY2026, on 12 actions (5 new awards), +513% vs FY2025. Its largest program was 93.866 · Aging Research ($1.5M).

Assistance · FY2026
$3.8M
New awards
5
Actions
12
Since FY2021
$6.8M

Assistance by fiscal year

  1. 253.8KFY2021
  2. 837.8KFY2022
  3. 817.1KFY2023
  4. 536.3KFY2024
  5. 613.7KFY2025
  6. 3.8MFY2026

By type

  1. Grants$3.8M100%

Top programs

  1. 93.866 · Aging Research$1.5M40%
  2. 93.859 · Biomedical Research and Research Training$1.3M35%
  3. 93.855 · Allergy and Infectious Diseases Research$607.1K16%
  4. 93.394 · Cancer Detection and Diagnosis Research$306.9K8.2%

Awarding agencies

  1. National Institutes of Health$3.8M100%
    Department of Health and Human Services

Largest awards

  1. A UNIVERSAL DROPLET MICROFLUIDIC PLATFORM FOR ULTRAHIGH-THROUGHPUT BIOCATALYST EVOLUTION - ABSTRACT THE ADVANCE OF BIOTECHNOLOGY IS…$1.7M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Sep 16, 2022 – Feb 9, 2026· R42GM143989
  2. A UNIVERSAL PLATFORM FOR ULTRAHIGH-THROUGHPUT BIOCATALYST EVOLUTION WITH MICRO-MASS SPECTROMETRY - ABSTRACT THE ADVANCEMENT OF…$1.3M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Jul 21, 2025 – Aug 20, 2026· R44GM161309
  3. FIND-SEQ: A NOVEL CELL SORTING TECHNOLOGY TO ENABLE INVESTIGATION OF RARE CELLS IN PRIMARY HUMAN TISSUES - ABSTRACT RARE CELLS, SUCH AS…$1.3M
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 12, 2025 – Aug 27, 2026· R44AG091101
  4. ASTROTARGET™ ASTRO-ENRICHMENT KIT: A MICROFLUIDIC-FREE PLATFORM FOR HIGH-THROUGHPUT RARE-ASTROCYTE ISOLATION AND MULTI-OMIC PROFILING FROM…$506.5K
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 8, 2026 – Sep 8, 2026· R44AG102286
  5. HIVE-SEQ: A NOVEL OMICS TECHNOLOGY TO PROFILE THOUSANDS OF SINGLE HIV-POSITIVE CELLS - ABSTRACT IDENTIFYING AND FULLY CHARACTERIZING CELLS…$307.1K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 19, 2026 – Aug 19, 2026· R44AI195215
  6. ULTRAHIGH-THROUGHPUT CELL INTERACTION SCREENING TO ADVANCE CAR-T THERAPEUTIC DEVELOPMENT - ABSTRACT CHIMERIC ANTIGEN RECEPTOR T-CELL…$306.9K
    93.394 · Cancer Detection and Diagnosis Research· National Institutes of Health· Project grant· Aug 7, 2026 – Aug 7, 2026· R44CA310740

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. FLAG BIO, INC$594.6K
    EAST AURORA, NY · 99.9% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. ENEPRET INCORPORATED$599.5K−100% in FY2026
    LEXINGTON, KY · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. BIG EYE DIAGNOSTICS INC$599.6K−100% in FY2026
    SAN DIEGO, CA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.